Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) Bundle
Zhangzhou Pientzehuang Pharmaceutical's recent numbers demand attention: Q3 2025 revenue plunged to CNY 2.06 billion (a 26.28% YoY decline) while TTM revenue sits at CNY 9.78 billion (down 10.35% year-over-year) despite CNY 10.79 billion in 2024 sales (up 7.25% vs. 2023); profitability also softened with Q3 net profit attributable to shareholders at CNY 687 million (-28.82% YoY) and TTM net income of CNY 2.42 billion (-20.74%), yielding a TTM net margin of 24.74% and an operating margin of 36.85% alongside ROE of 16.27% and EPS (TTM) of CNY 4.01 (P/E ~39.99-42.62); the balance sheet shows total debt of CNY 1.06 billion vs. cash and equivalents of CNY 3.27 billion (net cash ~CNY 2.21 billion), a conservative debt-to-equity of 0.07, a strong current ratio of 5.00 but a 58.80% drop in cash year-over-year, and operating cash flow (TTM) of CNY 1.7 billion; valuation multiples are rich-market cap CNY 103.09 billion, P/S 10.33, EV/EBITDA ~39.98 and a Peter Lynch fair value of CNY 70.86 versus current price CNY 169.34-while regulatory, cost, competition, policy and FX risks sit beside international expansion, R&D investment, partnerships and channel diversification as key growth levers; dive into the full breakdown to see which signals matter most for investors.
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) - Revenue Analysis
Zhangzhou Pientzehuang Pharmaceutical., Ltd reported mixed top-line trends across 2024 and the trailing twelve months into 2025, with a pronounced revenue contraction in Q3 2025 driven by the pharmaceutical manufacturing segment.
- Q3 2025 revenue: CNY 2.06 billion (down 26.28% YoY).
- TTM revenue: CNY 9.78 billion (down 10.35% YoY).
- FY 2024 revenue: CNY 10.79 billion (up 7.25% vs. 2023).
- Market cap (12-Dec-2025): CNY 103.09 billion; P/S ratio: 10.33.
- Revenue per employee: ~CNY 3.44 million, indicating high workforce productivity.
The Q3 2025 decline is specifically attributed to reduced sales volumes and compression in gross margins within the pharmaceutical manufacturing business, suggesting product mix, pricing pressure, or cost inflation impacted factory-level profitability and sales execution.
| Metric | Value | YoY / Comment |
|---|---|---|
| Q3 2025 Revenue | CNY 2.06 billion | -26.28% YoY |
| TTM Revenue | CNY 9.78 billion | -10.35% YoY |
| FY 2024 Revenue | CNY 10.79 billion | +7.25% vs. 2023 |
| Revenue per Employee | CNY 3.44 million | Operational efficiency indicator |
| Market Capitalization (12-Dec-2025) | CNY 103.09 billion | Implied P/S = 10.33 |
Investors focusing on valuation and operational drivers should note the divergence between solid FY 2024 growth and the sharp Q3 2025 decline; monitoring upcoming quarterly releases for margin recovery or further sales deterioration will be critical. For related investor ownership and positioning context, see: Exploring Zhangzhou Pientzehuang Pharmaceutical., Ltd Investor Profile: Who's Buying and Why?
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) - Profitability Metrics
Key profitability indicators for Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) show mixed performance: solid operating efficiency alongside notable declines in net earnings year-over-year.
- Q3 2025 net profit attributable to shareholders: CNY 687 million (down 28.82% YoY).
- TTM net income: CNY 2.42 billion (down 20.74% YoY).
- TTM net profit margin: 24.74% (decline vs. prior year).
- TTM operating margin: 36.85% (indicates strong operational efficiency).
- Return on equity (ROE): 16.27%.
- TTM earnings per share (EPS): CNY 4.01; P/E ratio: 42.62.
| Metric | Value | Period | YoY Change |
|---|---|---|---|
| Net profit attributable to shareholders | CNY 687 million | Q3 2025 | -28.82% |
| Net income (TTM) | CNY 2.42 billion | TTM | -20.74% |
| Net profit margin (TTM) | 24.74% | TTM | Declined vs. prior year |
| Operating margin (TTM) | 36.85% | TTM | Strong |
| Return on equity (ROE) | 16.27% | TTM | - |
| EPS (TTM) | CNY 4.01 | TTM | - |
| Price-to-Earnings (P/E) | 42.62 | TTM | - |
For context on company background and strategy that help drive these metrics, see: Zhangzhou Pientzehuang Pharmaceutical., Ltd: History, Ownership, Mission, How It Works & Makes Money
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) - Debt vs. Equity Structure
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) shows a conservative leverage profile driven by substantial cash reserves relative to outstanding debt, producing a net cash position that supports liquidity and strategic flexibility.
| Metric | Amount (CNY) | Notes |
|---|---|---|
| Total debt | 1,060,000,000 | As of September 2024; up from 843,400,000 year-over-year |
| Cash and cash equivalents | 3,270,000,000 | Highly liquid balance supporting operations and investments |
| Net cash position | 2,210,000,000 | Cash minus total debt (3.27b - 1.06b) |
| Debt-to-equity ratio | 0.07 | Debt conservative relative to equity |
| Interest coverage ratio | 78.99 | Very strong ability to meet interest obligations |
| Total liabilities | 3,100,000,000 | Includes current and non-current components |
| Current liabilities | 3,100,000,000 | Short-term obligations |
| Non-current liabilities | 289,500,000 | Long-term obligations |
| Total assets | 4,120,000,000 | Asset base supporting operations |
| Total equity | 3,050,000,000 | Shareholders' equity |
- Net cash position of CNY 2.21b provides a buffer for capex, R&D, and potential M&A without needing material new debt.
- Debt-to-equity at 0.07 and interest coverage of 78.99 indicate minimal refinancing risk and very low interest burden relative to operating earnings.
- Current liabilities reported at CNY 3.10b suggest working-capital and short-term obligations warrant monitoring despite overall liquidity.
For context on corporate direction and strategic priorities that interact with capital structure decisions, see Mission Statement, Vision, & Core Values (2026) of Zhangzhou Pientzehuang Pharmaceutical., Ltd.
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) - Liquidity and Solvency
Key liquidity and solvency metrics for Zhangzhou Pientzehuang illustrate a company with strong short-term coverage, conservative leverage, and robust operating cash generation despite a notable decline in cash balances.
| Metric | Value |
|---|---|
| Current Ratio | 5.00 |
| Quick Ratio | 1.15 |
| Cash & Cash Equivalents YoY Change | -58.80% |
| Operating Cash Flow (TTM) | CNY 1.7 billion |
| Debt-to-Equity Ratio | 7.04% |
| Net Income (Latest Quarter) | CNY 687.04 million |
| Earnings Per Share (Latest Quarter) | CNY 1.13 |
- Current ratio 5.00: ample short-term asset coverage of current liabilities, reducing liquidity risk.
- Quick ratio 1.15: adequate immediate liquidity excluding inventories, sufficient for near-term obligations.
- Cash decline of 58.80%: raises questions on cash deployment - investment, acquisitions, working capital, or one-off outflows.
- Operating cash flow CNY 1.7B (TTM): strong core operations converting revenue into cash, supporting operations and capital allocation.
- Debt-to-equity 7.04%: conservative capital structure with low financial leverage and limited interest burden.
- Latest quarter profitability: net income CNY 687.04M and EPS CNY 1.13, confirming earnings alongside solid cash flow.
For deeper context on shareholder composition and recent investor activity, see: Exploring Zhangzhou Pientzehuang Pharmaceutical., Ltd Investor Profile: Who's Buying and Why?
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) - Valuation Analysis
Zhangzhou Pientzehuang Pharmaceutical presents a premium market valuation across multiple commonly used metrics. The following breakdown highlights how the market is pricing the company relative to earnings, book value, sales and cash-flow proxies, alongside a simple fair-value estimate.- TTM P/E: 39.99 - valuation reflects strong investor willingness to pay for current earnings.
- Forward P/E: 33.02 - market-implied earnings growth expectations compress the forward multiple versus TTM.
- P/B: 6.78 - shares trade at a substantial premium to reported book value.
- EV/EBITDA: 39.98 - very high multiple, indicating stretched valuation on an enterprise cash-flow basis.
- EV/Revenue: 10.45 - market assigns a high revenue multiple versus peers/industry norms.
- Market cap (12‑Dec‑2025): CNY 103.09 billion; P/S: 10.33 - expensive on a sales basis.
- Peter Lynch fair value estimate: CNY 70.86 vs. market price CNY 169.34 - signals potential overvaluation under this heuristic.
| Metric | Value | Unit / Note |
|---|---|---|
| Price (current) | CNY 169.34 | Share price |
| Market Capitalization | CNY 103.09 billion | As of 12‑Dec‑2025 |
| TTM P/E | 39.99 | Trailing 12 months |
| Forward P/E | 33.02 | Consensus forward EPS |
| P/B | 6.78 | Price / Book |
| EV/EBITDA | 39.98 | Enterprise value multiple |
| EV/Revenue | 10.45 | Enterprise value / Sales |
| P/S | 10.33 | Price / Sales |
| Peter Lynch Fair Value | CNY 70.86 | Estimated |
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) - Risk Factors
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) faces a range of material risks that can affect revenue, margins and valuation. Below are primary risk drivers, quantified impact estimates, and practical indicators investors should monitor.- Regulatory approval and compliance risk: Time-to-market and approval probability directly affect product revenue streams. Typical approval timelines for new TCM/pharmaceutical products can range from 12-36 months; a 6-18 month delay can defer revenue recognition by one fiscal year.
- Raw material cost volatility: Key herbal inputs and excipients are commodity-driven. Historical swings in herb prices have produced +/-10-25% annual cost volatility for TCM producers, which can compress gross margins if not offset by pricing power.
- Competitive pressure: Domestic generics and international entrants pressure pricing and market share; new product launches and price cuts can reduce unit sales growth by 3-10% in affected product lines.
- Healthcare policy and reimbursement changes: Reimbursement rate adjustments and inclusion/exclusion from provincial/city-level formularies can change demand by 5-30% for covered products.
- Macroeconomic sensitivity: In economic downturns, discretionary health and OTC spending may decline; consumer-facing product lines may see volume drops of 5-15% in recessionary periods.
- Foreign exchange exposure: Export sales and imported raw materials expose the company to FX swings; a 5-10% CNY depreciation/appreciation can alter cost of goods sold or reported export revenue materially.
| Risk | Typical Quantitative Indicator | Estimated Impact Range | Monitoring Metric |
|---|---|---|---|
| Regulatory approval delays | Median approval timeline (months) | 12-36 months; revenue deferral 0-100% for pipeline product | Number of pending NDA/MA applications; average approval time |
| Raw material cost volatility | YoY raw material cost change (%) | ±10-25% | Raw material cost as % of COGS; supplier concentration ratio |
| Competitive pressure | Market share change (%) | -3% to -10% for vulnerable SKUs | Channel sell-through rates; price index vs. peers |
| Reimbursement & policy | Change in reimbursement rate (%) | -5% to -30% demand impact | Inclusion in national/provincial formularies; reimbursement pricing reviews |
| Economic downturn | Consumer healthcare spending change (%) | -5% to -15% volume impact | Retail OTC sell-through; consumer sentiment indices |
| Foreign exchange | FX move vs. CNY (%) | ±5-10% P&L impact on exposed items | Share of revenue/costs denominated in foreign currency |
- Concentration and supplier risk: If top 3 suppliers represent >40% of key herbal inputs, supply disruption can spike procurement costs and cause production interruptions.
- Product portfolio concentration: High reliance on a few flagship SKUs increases vulnerability to policy or competitive shocks; a 20-40% revenue concentration in top SKUs magnifies downside.
- Pricing and margin sensitivity: A 5% cut in ex-factory price on key products can reduce operating profit by several percentage points given typical gross margins in TCM/pharma segments.
- Quarterly revenue growth (%) and segment breakdown - watch any quarter-on-quarter decline >5% in core segments.
- Gross margin (%) and raw material costs as % of revenue - margin compression >200 bps year-over-year signals raw input pressure or pricing erosion.
- R&D and regulatory pipeline status - number of pending approvals and expected commercialization dates.
- Export revenue share (%) and net FX exposures - if export share >10%, FX moves become material.
- Inventory days and receivable days - rising DSO/DIO may indicate provincial reimbursement delays or channel destocking.
- Diversification of supplier base and hedging policies for key commodities/FX.
- Expansion into reimbursed hospital channels and richer product mixes to reduce OTC sensitivity.
- Investment in regulatory affairs to accelerate filings and defend formulary positions.
- Price optimization and promotional strategies to protect volume while preserving margins.
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) - Growth Opportunities
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) sits at the intersection of traditional Chinese medicine (TCM) heritage and modern healthcare demand. Below are concrete growth opportunities, supported by market and operational numbers that can guide investor expectations and strategic choices.
- Expansion into international markets can drive revenue growth by tapping markets where TCM and herbal supplements are gaining traction.
- Investment in research and development can lead to new product offerings and higher-margin proprietary formulations.
- Strategic partnerships and collaborations can accelerate market access and reduce time-to-market for new products.
- Diversification into health supplements and personal care products can open new revenue streams and lower exposure to single-product cycles.
- Adoption of digital marketing strategies can increase brand visibility and lower customer acquisition cost (CAC).
- Enhancing distribution channels, including online platforms, can improve sales performance and geographic reach.
Relevant market and company-related metrics to quantify these opportunities:
| Metric | Value / Estimate | Source / Note |
|---|---|---|
| China TCM market size (2024 est.) | RMB 300-400 billion | National industry reports (market-wide estimate) |
| Global dietary supplements market (2021) | USD 150 billion; projected USD 230 billion by 2027 | Industry forecasts for supplements demand growth |
| Pientzehuang online sales share (2023 est.) | 15%-25% of total revenue | Sector shift toward e-commerce for Chinese OTC and TCM brands |
| R&D spend benchmark for pharma/TCM players | 3%-7% of revenue (typical range) | Global pharma/consumer health benchmarks |
| Addressable new-market revenue (3-year conservative scenario) | +RMB 200-400 million incremental revenue | International expansion + supplements diversification |
| Addressable new-market revenue (3-year aggressive scenario) | +RMB 800 million-1.5 billion incremental revenue | Fast rollout: e-commerce, partnerships, and expanded SKUs |
Practical levers and expected impacts (quantified where possible):
- International expansion
- Initial target regions: Southeast Asia, Greater China diaspora markets, selected EU/US natural health channels.
- Near-term revenue uplift: pilot exports could add RMB 50-150 million in year 1; scalable to several hundred million within 3 years under a focused rollout.
- R&D and new product pipelines
- Raising R&D spend to 5% of revenue could produce 2-4 new high-potential SKUs within 24-36 months.
- Successful proprietary products typically command 10-25 percentage points higher gross margin than commoditized OTC products.
- Strategic partnerships
- Co-branding or licensing with international distributors can reduce market-entry CAPEX and accelerate revenue recognition by 6-12 months.
- Diversification into supplements & personal care
- Targeted product lines (e.g., herbal supplements, topical care) can aim for 10-20% of overall product mix within 2-3 years, contributing to margin stabilization.
- Digital marketing & omnichannel distribution
- Investing in direct-to-consumer (DTC) channels and social commerce can reduce CAC by 15-30% over two years versus legacy channel-heavy models.
- Higher online penetration correlates with improved SKU-level margins due to lower trade discounts.
Illustrative three-year scenario table for incremental revenue from growth initiatives (RMB):
| Initiative | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| International exports (pilot → scale) | 50,000,000 | 150,000,000 | 350,000,000 |
| New R&D-derived SKUs | 20,000,000 | 80,000,000 | 180,000,000 |
| Supplements & personal care line | 30,000,000 | 120,000,000 | 300,000,000 |
| Enhanced online & omnichannel sales | 40,000,000 | 140,000,000 | 320,000,000 |
| Total incremental revenue | 140,000,000 | 490,000,000 | 1,150,000,000 |
Key KPIs to monitor while executing these growth strategies:
- Revenue CAGR from new markets and product lines (target 15%+ for new segments).
- R&D spend as % of revenue (target 4%-6% to sustain pipeline).
- Gross margin improvement from premium SKUs (+5-12 percentage points).
- Online sales share growth (target 30%+ within 3 years for resilient omni-channel mix).
- Return on invested capital (ROIC) for partnerships and channel expansion (target >10%).
For alignment with corporate purpose and to evaluate how these growth levers fit within long-term strategy, see: Mission Statement, Vision, & Core Values (2026) of Zhangzhou Pientzehuang Pharmaceutical., Ltd.
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.